The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, obesity & metabolism [Diabetes Obes Metab] Journal article

Title	The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Author(s)	Hanefeld M
Institution	GWT-TUD GmbH, Centre for Clinical Studies, Department of Metabolic Research and Endocrinology, Dresden Technical University, Dresden, Germany.
Source	Diabetes Obes Metab 2009 Jun 10.
Abstract	Pioglitazone, a thiazolidinedione, has established efficacy in improving glycaemic control in patients with type 2 diabetes. Pioglitazone also improves components of the mixed dyslipidaemia profile common in these patients, as typified by raised levels of plasma triglycerides, low levels of HDL cholesterol (HDL-C) and a raised proportion of LDL cholesterol (LDL-C) occurring as the small dense subfraction. In head-to-head trials, pioglitazone has consistently shown superior benefits on LDL-C and HDL-C as well as triglycerides compared with rosiglitazone and sulphonylureas. Pioglitazone used as monotherapy or combination therapy reduces levels of small dense LDL(3) particles while raising levels of larger and less atherogenic LDL fractions. In addition, pioglitazone reduces cholesterol load and particle numbers of LDL(3). Importantly, the differential effects of pioglitazone on LDL subfractions are complimentary and additive to those of simvastatin. Pioglitazone increases total HDL-C levels by 10-20%, mainly because of an increase in the larger HDL(2) subfraction. Pioglitazone also significantly reduces plasma triglyceride levels by 10-25%. In recent studies, pioglitazone significantly reduced carotid and coronary atherosclerosis compared with the sulphonylurea glimepiride. The antidyslipidaemic effects of pioglitazone - in particular, improvements in HDL-C and reduction of small dense LDL(3)- may have contributed to these effects.
Language	ENG
Pub Type(s)	JOURNAL ARTICLE
PubMed ID	19519869

Advertise on this site.